As an investor's capital grows in an illiquid space like micro-caps, they must hold positions longer or diversify. An extended duration forces a shift in focus from short-term plays to higher-quality businesses capable of sustained performance over time.

Verdad Capital's research shows biotech stocks heavily owned by multiple specialist funds significantly outperform those with none. This "consensus" among experts acts as a powerful quality screen in a sector where traditional financial metrics are useless, as stocks with zero specialist ownership generate near-zero returns.

The current public market isn't an indiscriminate bull run. It rewards strong data and punishes failure, creating an environment where deep-domain specialty investors, who can discern true value, thrive over generalists.

Even with a strong IPO window, many biotech investors aren't seeing universal gains. The market is rewarding specific, often non-obvious takeouts and catalyst-driven events, favoring deep diligence over passive investing, making it an 'inefficient' market.

Contrary to most industries, scale is not a decisive advantage in drug discovery. Wellington's Jean Hynes notes that small, nimble biotech companies discover roughly half of all new drugs. This creates a perpetual opportunity for investors to back small firms that can generate massive value.

The dominance of passive investing (~65% of the market) and the decline of sell-side research have created a structural inefficiency in small-cap stocks ($500M-$2B). With fewer active managers doing the work, valuations in this segment are extremely attractive, creating significant opportunities for diligent investors.

It's not enough to believe a drug trial will be positive. To generate true alpha, an investor must also have a well-researched, specific explanation for what misconceptions or concerns are causing other market participants to misprice the asset.

Market efficiency increases with company size and liquidity. Therefore, the excess returns (alpha) from investment factors like value are significantly larger in the inefficient micro-cap space. For large-caps, the market is so efficient that factor premiums are minimal, making low-cost indexing a superior strategy.

Sir John Templeton's success in 1960s Japan reveals a key pattern: the biggest opportunities lie where volatility and a lack of information deter mainstream investors. These factors create significant mispricings for those willing to do the necessary but difficult research, such as in today's micro-cap markets.